期刊
DRUG DISCOVERY TODAY
卷 24, 期 1, 页码 272-278出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.08.010
关键词
-
资金
- National Institutes of Health Intramural Research Program at the National Center for Advancing Translational Sciences
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIATR000018] Funding Source: NIH RePORTER
Personalized drug screening (PDS) of approved drug libraries enables rapid development of specific small-molecule therapies for individual patients. With a multidisciplinary team including clinicians, researchers, ethicists, informaticians and regulatory professionals, patient treatment can be optimized with greater efficacy and fewer adverse effects by using PDS as an approach to find remedies. In addition, PDS has the potential to rapidly identify therapeutics for a patient suffering from a disease without an existing therapy. From cancer to bacterial infections, we review specific maladies addressed with PDS campaigns. We predict that PDS combined with personal genomic analyses will contribute to the development of future precision medicine endeavors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据